Amgen Presents New AMG 510 Clinical Data Across Multiple Solid Tumors During ASCO20 Virtual Scientific Program
THOUSAND OAKS, Calif., May 29, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the CodeBreaK 100 clinical development program evaluating investigational AMG 510 (proposed INN so
BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
CAMBRIDGE, Mass. and BEIJING, China, May 29, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing inno
GSK Announces Intention to Produce 1 Billion Doses of Pandemic Vaccine Adjuvant in 2021 to Support Multiple COVID-19 Vaccine Collaborations
London UK 28 May 2020 -- GSK today confirmed its intention to manufacture 1 billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 v
ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
EL SEGUNDO, Calif., May 27, 2020 – NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announ
FDA Approves Gemtesa (vibegron) Tablets for the Treatment of Patients with Overactive Bladder (OAB)
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dec. 23, 2020 -- Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Ap
Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia
South San Francisco, CA -- May 27, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the initiation of a global Phase III, randomized, double-blind, multicen
DREAMM-2 and DREAMM-6 Data at ASCO Reinforce the Potential of GSK’s Investigational Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma
London UK May 27, 2020 -- GlaxoSmithKline (GSK) plc today announced new data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical programme, which further highlight the pote
Novartis Announces New Late-Breaking Ofatumumab Data at EAN Underscoring Commitment to Advancing Treatment of Relapsing Forms of Multiple Sclerosis (RMS)
EAST HANOVER, N.J., May 27, 2020 /PRNewswire/ -- Novartis announced today that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the 6th
Anivive Repurposes Veterinary Drug GC376 for COVID-19 And Submits Pre-IND to FDA
LONG BEACH, Calif. -- May 26, 2020 -- Anivive Lifesciences, a biotechnology company focused on developing first-in-class therapeutics for veterinary patients, has filed a pre-Investigational New Drug
Merck to Announce Multiple Scientific Efforts to Combat COVID-19
KENILWORTH, N.J.--(BUSINESS WIRE) May 26, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19:
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE) May 26, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology compa
IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) May 26, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and IAVI, a nonprofit scientific research organization dedicated
News
- CLINIEXPERT -
Int'l Clinical Service Expert
We are the leader
Because of our professionism
